All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Lenalidomide/Rituximab Regimens Show Encouraging Responses in Relapsed/Refractory Follicular Lymphoma, But Slow Accrual Axes Study

December 21st 2022

The regimen of lenalidomide in combination with rituximab with bendamustine are effective therapies for relapsed/refractory follicular lymphoma, with high rates of overall and complete metabolic response by PET, according to data from the randomized phase 2 HOVON110/Rebel trial.

Fluorouracil Is Inappropriate for Optimal Adjuvant Chemotherapy in High-Risk Early Breast Cancer

December 21st 2022

Updated results from the phase 3 GIM 2 study confirm previous findings showing that fluorouracil should not be a part of adjuvant chemotherapy for patients with high-risk early breast cancer.

Scientists Map Genetic Evolution of Chronic Lymphocytic Leukemia to Richter Syndrome

December 21st 2022

In a new study, scientists reveal for the first time the genomic differences between chronic lymphocytic leukemia and Richter's, the molecular pathways by which Richter's emerges, and the existence of multiple subtypes of the disease.

European Commission Approves Olaparib Plus Abiraterone and Prednisone/Prednisolone for mCRPC

December 21st 2022

The European Commission has approved the combination of olaparib plus abiraterone acetate and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated.

FDA Approves FoundationOne® Liquid CDx as a Companion Diagnostic for TKIs in EGFR-Mutant NSCLC

December 21st 2022

The FDA has approved the FoundationOne® Liquid CDx as a companion diagnostic to identify patients with non–small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R substitutions.

Overall Survival Is a Highly Relevant but Potentially Problematic End Point in Randomized Trials

December 21st 2022

Overall survival is a critically relevant end point in randomized oncology clinical trials, but its interpretation is often not as straightforward as some may wish to acknowledge.

Continued Development of Oral SERDs Could Help Reshape ER+/HER2- Breast Cancer Treatment

December 21st 2022

Virginia G. Kaklamani, MD, discusses the ongoing investigation of novel oral SERDs in patients with ER-positive/HER2-negative breast cancer, the remaining unmet needs for this patient population, and ongoing trials aiming to further understand the optimal use of oral SERDs.

FDA Expands Approval of Pemetrexed Injection for Metastatic NSCLC Without EGFR/ALK Aberrations

December 20th 2022

The FDA has approved an additional indication for pemetrexed by injection, an alternative to standard pemetrexed, in combination with pembrolizumab and platinum-based chemotherapy for the initial treatment of patients with metastatic, nonsquamous non–small cell lung cancer without EGFR or ALK genomic tumor aberrations.

Obecabtagene Autoleucel Meets Primary End Point of ORR in R/R B-cell Acute Lymphoblastic Leukemia

December 20th 2022

Obecabtagene autoleucel elicited an overall remission rate of 70% in 50 efficacy-evaluable adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, meeting the primary end point of the phase 2 FELIX trial.

FDA Accepts sBLAs for Enfortumab Vedotin/Pembrolizumab in Advanced Urothelial Cancer

December 20th 2022

The FDA has granted a priority review to a supplemental biologics license applications for enfortumab vedotin and pembrolizumab used in combination for the treatment of patients with locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-containing chemotherapy.

Neoadjuvant Treatment Sequencing Warrants Personalized Considerations in Rectal Cancer

December 20th 2022

Melissa A. Lumish, MD, discusses emerging treatment strategies that could lead to more individualized treatment plans for patients with rectal cancer.

NICE Recommends Trastuzumab Deruxtecan for Previously Treated HER2+ Metastatic Breast Cancer

December 20th 2022

The United Kingdom’s National Institute for Health and Care Excellence has endorsed trastuzumab deruxtecan for use within the Cancer Drugs Fund for adult patients with HER2-positive, unresectable or metastatic breast cancer following at least 1 anti-HER2 treatment.

Glofitamab Induces 39% CR Rate in Relapsed/Refractory DLBCL

December 20th 2022

Glofitamab, an investigational CD20xCD3 T-cell engaging bispecific antibody, demonstrated promising results in patients with relapsed/refractory diffuse large B-cell lymphoma who received at least 2 prior lines of therapy.

Zanidatamab Elicits Responses in Previously Treated HER2-Amplified Biliary Tract Cancers

December 20th 2022

Zanidatamab monotherapy produced responses in previously treated patients with HER2-amplified and -expressing biliary tract cancers.

Thrombocytopenia Is Associated With High Levels of Fatigue in Myelofibrosis

December 20th 2022

Jeanne M. Palmer, MD, discusses a retrospective analysis of the PERSIST-1 and PAC203 trials, the symptoms that were analyzed across patient populations, and what the findings from this research indicate about the relationship between low platelet counts and symptoms such as fatigue in myelofibrosis.

Durvalumab Misses OS End Point in PEARL Trial in Advanced, PD-L1–High NSCLC

December 19th 2022

Durvalumab monotherapy failed to elicit a statistically significant improvement in overall survival vs platinum-based chemotherapy as frontline treatment in patients with stage IV non–small cell lung cancer with at least 25% positivity of PD-L1 on tumor cells, or in a subgroup of patients at low risk of early mortality.

UK Accepts Marketing Authorization Application for Sugemalimab in Metastatic NSCLC

December 19th 2022

The United Kingdom’s Medicines and Healthcare Products Regulatory Agency has accepted a marketing authorization application seeking approval for sugemalimab plus chemotherapy as first-line treatment for patients with metastatic non–small cell lung cancer.

COM701 Plus Nivolumab Confers Modest Efficacy in Metastatic MSS-CRC

December 19th 2022

COM701 plus nivolumab demonstrated modest antitumor activity but a favorable safety profile in patients with metastatic microsatellite stable colorectal cancer.

Fox Chase Graduate Student Billy Truong Recognized With ASH Abstract Achievement Award

December 19th 2022

Billy Truong, a doctoral candidate at Fox Chase Cancer Center, was awarded the American Society of Hematology Abstract Achievement Award for a poster that he presented at the 64th ASH Annual Meeting and Exposition.

European Commission Approves Trastuzumab Deruxtecan in Pretreated HER2+ Advanced Gastric/GEJ Cancer

December 19th 2022

The European Commission has approved fam-trastuzumab deruxtecan-nxki as monotherapy for the treatment of patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.